Absci falls after Q2 revenue misses estimates

BUZZ-Absci falls after Q2 revenue misses estimates

** Shares of drug developer Absci ABSI.O fall 1.4% to $9.3

** Co posts Q2 revenue of $318,000, sharply below analysts' estimates of $1.2 mln

** Reports increase in R&D expenses of $22.6 mln compared to $20.5 mln last year, primarily driven by advancement of ABSI's internal programs

** Brokerage TD Cowen says revenue is expected to nearly halve due to lower collaboration and milestone payments, underscoring its reliance on partner-funded revenue

** Says investors are pivoting the attention to its ABS-201 hair-loss data expected later this year- TD Cowen

** Nine of 10 brokerages rate the stock "buy" or higher and one "hold"; median PT is $14- LSEG data

** Including session's move, stock has more than doubled in value, YTD


(Reporting by Anand Gopal in Bengaluru)

((anandgopal.r@thomsonreuters.com))

Recent news on AbSci

See all news